Trial · NCT04492618
Ruxolitinib Cream in the Treatment of Cutaneous Necrobiosis Lipoidica
NCT04492618, Phase 2, Completed, Aaron R. Mangold; results first posted 2023-02-08
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Ruxolitinib Cream in the Treatment of Cutaneous Necrobiosis Lipoidica. Trials, record NCT04492618. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT04492618
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Ruxolitinib Cream in the Treatment of Cutaneous Necrobiosis Lipoidica
- NCT number
- NCT04492618
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 12 participants, actual
- Lead sponsor
- Aaron R. Mangold
- Conditions
- Necrobiosis Lipoidica
- Interventions
- Ruxolitinib
- First posted
- 2020-07-30
- Last updated
- 2023-02-08
- Results first posted
- 2023-02-08
Source ClinicalTrials.gov
Registered outcomes1
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change in Mean Necrobiosis Lipoidica (NL) Lesion Score | Baseline, week 12 | The NL skin scoring system examines the index treatment lesion on a scale from 0 (none) to 3 (severe) for each of the following areas: erythema, infiltration, ulceration, and pain. A total possible score of 0-12, with lower scores indicating none and higher scores indicating more severe. |
Source ClinicalTrials.gov
Outcomes1
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Change in Mean Necrobiosis Lipoidica (NL) Lesion Score | Baseline, week 12 | 1 Subject withdrew. Week 12 data was not collected nor analyzed | score on a scale | MEAN |
Source ClinicalTrials.gov
Results by group1
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Change in Mean Necrobiosis Lipoidica (NL) Lesion Score | Necrobiosis Lipoidica | -2.7 | Standard Deviation 1.6 | score on a scale |
Source ClinicalTrials.gov
Participant flow3
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Necrobiosis Lipoidica | 12 | |
| Overall Study | COMPLETED | Necrobiosis Lipoidica | 11 | |
| Overall Study | NOT COMPLETED | Necrobiosis Lipoidica | 1 |
Source ClinicalTrials.gov
Adverse events14
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Abdominal pain | Gastrointestinal disorders | Necrobiosis Lipoidica | 1 | 12 | |
| other | Basal cell carcimona removal | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Necrobiosis Lipoidica | 1 | 12 | |
| other | Bronchitis | Respiratory, thoracic and mediastinal disorders | Necrobiosis Lipoidica | 1 | 12 | |
| other | Burning sensation | Skin and subcutaneous tissue disorders | Necrobiosis Lipoidica | 1 | 12 | |
| other | Burning sensation on NL spots | Skin and subcutaneous tissue disorders | Necrobiosis Lipoidica | 1 | 12 | |
| other | Cold Symptoms | Respiratory, thoracic and mediastinal disorders | Necrobiosis Lipoidica | 1 | 12 | |
| other | Diarrhea | Gastrointestinal disorders | Necrobiosis Lipoidica | 1 | 12 | |
| other | Heaviness Bilateral legs | Musculoskeletal and connective tissue disorders | Necrobiosis Lipoidica | 1 | 12 | |
| other | Heightened sensitivity on lesions | Skin and subcutaneous tissue disorders | Necrobiosis Lipoidica | 1 | 12 | |
| other | Leg pain | Musculoskeletal and connective tissue disorders | Necrobiosis Lipoidica | 1 | 12 |
1 to 10 of 14Source ClinicalTrials.gov
See all 14 adverse eventsAdverse event totals3
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Necrobiosis Lipoidica | 0 | 12 |
| Total, other adverse events | Necrobiosis Lipoidica | 10 | 12 |
| Total, serious adverse events | Necrobiosis Lipoidica | 0 | 12 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT04492618
GET https://conductscience.org/api/trials/v1/NCT04492618/registered